Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer – Czech Republic Model Adaptation
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.